Beyond the Patient: The Importance of Rapid Molecular Detection to Help Healthcare Facilities Stay Ahead of Candida auris
September 9, 2026 - Lenexa, KS, USA
As Candida auris continues its rapid emergence across U.S. healthcare facilities, infection prevention teams are facing a pathogen unlike virtually any other fungal threat encountered in modern medicine. Multidrug resistant, highly transmissible, and remarkably persistent in the healthcare environment, C. auris has blurred the traditional distinction between patient infection and environmental contamination. The result is a growing recognition that successful containment requires visibility into both the patient and the environment.
Recent outbreak experiences from leading academic medical centers offer an important lesson: identifying colonized patients is only part of the equation. Understanding where C. auris lives, persists, and spreads within the healthcare environment may be equally important for preventing transmission.1,2
The Unique Challenge of C. auris
Unlike many fungal pathogens, C. auris behaves more like a multidrug resistant bacterial organism. It can spread directly between patients, survive on healthcare workers' hands, contaminate reusable equipment, and persist on environmental surfaces for extended periods. Healthcare facilities have documented contamination of bedrails, bedside tables, medical devices, windowsills, and other high-touch surfaces surrounding colonized patients.2,3
Adding to the challenge, many patients carrying C. auris are asymptomatically colonized. These individuals show no obvious signs of infection yet can shed the organism onto surrounding surfaces and unknowingly contribute to transmission within and between healthcare facilities.4,5
The CDC notes that C. auris can persist on patients and environmental surfaces for months and is not reliably eliminated by several commonly used disinfectants, particularly those relying solely on quaternary ammonium compounds.3,5
A Real-World Example: Seattle's Successful Containment Effort
A compelling example comes from Harborview Medical Center in Seattle, which successfully contained a C. auris outbreak over a six-month period without a single colonized patient progressing to symptomatic infection. The hospital identified 29 colonized patients through an aggressive screening initiative involving more than 11,000 tests. Rapid PCR-based screening reduced turnaround times from several days to approximately 20 hours, enabling earlier isolation and intervention.1
Perhaps most importantly, investigators discovered that approximately half of the colonized patients acquired C. auris in bed spaces previously occupied by positive patients, highlighting the critical role environmental contamination played in transmission. In response, Harborview implemented enhanced environmental cleaning protocols, ultraviolet disinfection, and ATP surface monitoring to verify cleaning effectiveness.1
The findings reinforce a growing understanding that environmental reservoirs can sustain transmission even when clinical infection rates remain low.
Why Patient Screening Matters
The first step in controlling C. auris is identifying who carries it.
Because colonized patients often have no symptoms, targeted surveillance programs have become an increasingly important component of infection prevention. Screening programs generally involve composite skin swabs from areas such as the axilla and groin, allowing facilities to identify colonized individuals and rapidly implement isolation precautions.5,6
Northwestern Medicine and Rush University System for Health have both adopted proactive screening programs focused on high-risk populations, including patients transferred from long-term care facilities and skilled nursing facilities. Northwestern additionally performs ongoing surveillance in units with elevated C. auris prevalence. These efforts are designed to identify colonized patients before widespread transmission occurs.2
Patient screening provides several benefits:
- Early identification of asymptomatic carriers
- Prompt initiation of contact precautions
- More informed room placement decisions
- Enhanced outbreak detection capabilities
- Better interfacility communication during patient transfers5,2
Turning Surveillance into Action: The Importance of Rapid Molecular Detection
As healthcare facilities expand their C. auris surveillance programs, the effectiveness of these initiatives ultimately depends on one critical factor: timely and accurate detection.
Traditional culture-based screening approaches can require several days before results become available, potentially delaying decisions around patient placement, contact precautions, and outbreak response. In contrast, molecular PCR-based methods can help infection prevention teams identify colonized patients more rapidly, allowing facilities to implement containment measures earlier in the transmission cycle. This principle was highlighted by Harborview Medical Center's successful outbreak response, where rapid PCR testing significantly reduced result turnaround times and supported faster infection control interventions.1
Eurofins Viracor offers molecular testing solutions designed to support healthcare facilities in the detection and surveillance of Candida auris.
Targeted Screening for Suspected Colonized Patients
For facilities conducting surveillance programs, the Candida auris Real-Time PCR assay can be performed on axilla, groin, or nares specimens, providing a targeted approach for identifying patients who may be colonized with C. auris. Colonization screening is increasingly recognized as a cornerstone of outbreak prevention because asymptomatic carriers can unknowingly shed the organism into the healthcare environment and contribute to ongoing transmission.5,6
Identification of colonized patients enables healthcare teams to:
- Initiate appropriate isolation precautions
- Optimize room placement decisions
- Enhance environmental cleaning efforts
- Improve interfacility communication during patient transfers
- Strengthen outbreak containment strategies
Looking Forward
As Candida auris continues to expand across healthcare settings, facilities are increasingly recognizing that successful prevention depends upon timely visibility into both patient colonization and environmental contamination mitigation. Active surveillance programs, robust environmental cleaning protocols, and rapid molecular diagnostic tools work together to form a comprehensive infection prevention strategy.
Solutions such as Eurofins Viracor's Candida auris Real-Time PCR assay and Candida Real-Time PCR Panel can help healthcare organizations identify potential reservoirs of transmission earlier, supporting the proactive interventions needed to contain this challenging pathogen before outbreaks occur.
When integrated into broader infection prevention programs, molecular testing can help healthcare facilities move from reactive outbreak management to proactive surveillance and containment.
References:
1. Twenter, P. (2026, August 19). Seattle hospital contained a C. auris outbreak in 6 months with zero infections. Becker's Hospital Review. https://www.beckershospitalreview.com/quality/infection-control/seattle-hospital-contained-a-c-auris-outbreak-in-6-months-with-zero-infections/
2. Jeffries, E. (2026, July 28). Rush, Northwestern detail their playbooks for C. auris. Becker's Hospital Review. https://www.beckershospitalreview.com/quality/infection-control/rush-northwestern-detail-their-playbooks-for-c-auris/
3. https://www.cdc.gov/candida-auris/hcp/infection-control/
4. https://www.cdc.gov/candida-auris/prevention/
5. https://www.cdc.gov/candida-auris/hcp/screening-hcp/
6. https://www.cdc.gov/candida-auris/screening/
7. Eurofins Viracor. Candida auris Real-Time PCR (Axilla, Groin, or Nares). https://www.eurofins-viracor.com/test-menu/33330-candida-auris-real-time-pcr-axilla-groin-or-nares/
8. Eurofins Viracor. Candida Real-Time PCR Panel. https://www.eurofins-viracor.com/test-menu/33306-candida-real-time-pcr-panel/
When you suspect an invasive fungal infection, one day can be the difference between life and death.
